Polygenic burden of Parkinson's disease risk stratifies the prognosis of isolated rapid-eye-movement disorder: A preliminary observational study.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
03 2022
Historique:
received: 20 12 2021
revised: 09 02 2022
accepted: 09 02 2022
pubmed: 27 2 2022
medline: 18 5 2022
entrez: 26 2 2022
Statut: ppublish

Résumé

Polygenic burden of Parkinson's disease (PD) risk single nucleotide polymorphisms (SNPs), is associated not only with PD development and age at onset, but also with higher PD penetrance in GBA and LRRK2 carriers. To assess the impact of polygenic burden of PD risk SNPs in isolated rapid-eye-movement disorder (iRBD). In this observational study using the data of the Parkinson's progression marker initiative, we retrospectively reviewed the records of iRBD patients of European-ancestry with genotype data for 90 PD risk SNPs available. We calculated the genetic risk score for PD (PD-GRS) as a weighted sum of those SNPs, and examined the association of PD-PRS with the subsequent course of iRBD patients. 37 IRBD patients (median age = 71.0 years, male = 65.4%) were included. Median follow-up years from the diagnosis was 6.8 years, and 14 patients (38.9%) developed overt α-synucleopathies during the follow-up period. PD-GRS was significantly associated with an increased phenoconversion risk [hazard ratio per +1 standard deviation (adjusted for age, sex, and baseline cognitive, motor, autonomic, and olfactory dysfunction as well as principal components 1 to 5 to account for the population stratification) = 7.4 (95% confidence interval, 1.6-34.6)]. Furthermore, iRBD patients with PD-GRS higher than the median showed an accelerated decline in motor function [standardized fixed-effects β coefficients of the interaction term = 0.08 (95% confidence interval, 0.02-0.14)]. Our study showed the intriguing possibility that the disease course of iRBD patients differed according to the degree of polygenic burden of PD risk SNPs, although future validation is warranted.

Sections du résumé

BACKGROUND
Polygenic burden of Parkinson's disease (PD) risk single nucleotide polymorphisms (SNPs), is associated not only with PD development and age at onset, but also with higher PD penetrance in GBA and LRRK2 carriers.
OBJECTIVES
To assess the impact of polygenic burden of PD risk SNPs in isolated rapid-eye-movement disorder (iRBD).
METHODS
In this observational study using the data of the Parkinson's progression marker initiative, we retrospectively reviewed the records of iRBD patients of European-ancestry with genotype data for 90 PD risk SNPs available. We calculated the genetic risk score for PD (PD-GRS) as a weighted sum of those SNPs, and examined the association of PD-PRS with the subsequent course of iRBD patients.
RESULTS
37 IRBD patients (median age = 71.0 years, male = 65.4%) were included. Median follow-up years from the diagnosis was 6.8 years, and 14 patients (38.9%) developed overt α-synucleopathies during the follow-up period. PD-GRS was significantly associated with an increased phenoconversion risk [hazard ratio per +1 standard deviation (adjusted for age, sex, and baseline cognitive, motor, autonomic, and olfactory dysfunction as well as principal components 1 to 5 to account for the population stratification) = 7.4 (95% confidence interval, 1.6-34.6)]. Furthermore, iRBD patients with PD-GRS higher than the median showed an accelerated decline in motor function [standardized fixed-effects β coefficients of the interaction term = 0.08 (95% confidence interval, 0.02-0.14)].
CONCLUSION
Our study showed the intriguing possibility that the disease course of iRBD patients differed according to the degree of polygenic burden of PD risk SNPs, although future validation is warranted.

Identifiants

pubmed: 35217383
pii: S1353-8020(22)00038-4
doi: 10.1016/j.parkreldis.2022.02.005
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-56

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Kazuto Tsukita (K)

Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan; Advanced Comprehensive Research Organization, Teikyo University, Itabashi, Tokyo, Japan. Electronic address: kazusan@kuhp.kyoto-u.ac.jp.

Haruhi Sakamaki-Tsukita (H)

Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Naoko Tachibana (N)

Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan; Department of Neurology and Center for Sleep-related Disorders, Kansai Electric Power Hospital, Osaka, Japan.

Ryosuke Takahashi (R)

Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH